CME Group Stock Price and Value Analysis

CME Group (NasdaqGS:CME) in our automated value investing analysis, with the cash flow history and price comparison below.

Key Facts

Advertisement helps keep Trendshare free for most readers.

Hold-time calculator

Estimate how long you need to hold CME Group to reach your target.

Target type

CME Free Cash Flow Trend

Free Cash Flow trendline for CME
Free Cash Flow trendline for CME Group
CSV

Based on historical returns, we believe that CME Group can grow its free cash at a rate of about 4%. That's positive!

AdvantagesDisadvantages
  • This company has stable growth.
  • This company is very stable.
  • This company has a low dividend yield.
  • This company is making money at a modest rate.
  • This stock looks overpriced.

Inside the CME Numbers

CME Price
(CME Group stock price per share)
$307.56
[?] CME Fair Price
(based on intrinsic value)
$153.84
[?] CME Safety Price (based on a variable margin of safety) $123.07
Try your own return

The fair price above uses a 10.1% discount rate, the long-run US stock return (10.1% geometric, 1926 to 2025, from Bessembinder's working paper, updated 2026-11-09), and 2.5% terminal growth. A higher rate suits a higher return target and gives a lower value.

Value per share:

[?] PE Ratio versus Sector 90% higher than other Financial Services stocks
[?] PE Ratio versus Industry 48% lower than other Capital Markets stocks
[?] Cash Yield 1.59%
[?] Free Cash Flow Jitter 17%
[?] Dividend Yield 1.68% (tax impact)
Shares Shorted 5,351,351

Insider Activity Summary

No open-market insider buys or sells are recorded for the last 12 months.

This stock has short interest! This means that people have shorted it.

Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.

As of the latest analysis, there are 5,351,351 shares shorted. With 353,023,031 shares available for purchase and an average trading volume over the past 10 trading days of 1,902,780, it would take at least 2.8 days for all of the short holders to cover their shorts.

Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth

Free Cash Flow by Fiscal Year

How to read this: free cash flow in plain terms, free cash flow jitter.

Each year names the SEC filer that reported it, so a change of filer shows up here.

Fiscal yearSEC filer (CIK)Free cash flow (USD millions)
2007 1156375 651
2008 1156375 1,015
2009 1156375 909
2010 1156375 1,189
2011 1156375 1,176
2012 1156375 1,053
2013 1156375 1,129
2014 1156375 1,143
2015 1156375 1,394
2016 1156375 1,609
2017 1156375 1,640
2018 1156375 2,332
2019 1156375 2,543
2020 1156375 2,569
2021 1156375 2,249
2022 1156375 2,901
2023 1156375 3,307
2024 1156375 3,574
2025 1156375 4,183

Download the yearly data as CSV.

Cash Conversion

How to read this: what free cash flow is, why earnings matter.

Over the 19 fiscal years from 2007 to 2025 with positive net income, operating cash flow totaled $39,317 million against net income of $37,145 million, or 1.06 times.

In 2025, operating cash flow was 1.05 times net income, compared with 1.41 times for the earliest three years (2007 to 2009).

In 2025, capital expenditures were $83.5 million, 2.0% of operating cash flow of $4,277 million, which leaves an estimated $4,194 million after capex. Across the 19 years with reported capex, it averaged 6.6% of operating cash flow. This uses that year's own capital expenditures, not the five-year average behind the free cash flow table, so the two can differ.

Cash conversion in 2025 was 1.05, at least 0.25 under the 1.41 earliest three-year ratio. Gaps like this come from non-cash gains or from cash tied up in receivables, inventory or other working capital.

Fiscal yearNet income (USD millions)Operating cash flow (USD millions)Capital expenditures (USD millions)Operating cash flow / net income
2007 659 814 164 1.24
2008 716 1,197 200 1.67
2009 826 1,083 158 1.31
2010 951 1,360 160 1.43
2011 1,812 1,346 172 0.74
2012 896 1,220 142 1.36
2013 977 1,281 126 1.31
2014 1,127 1,291 141 1.15
2015 1,247 1,533 114 1.23
2016 1,534 1,732 91.8 1.13
2017 4,063 1,751 81.9 0.43
2018 1,962 2,441 117 1.24
2019 2,117 2,673 246 1.26
2020 2,106 2,716 198 1.29
2021 2,637 2,402 127 0.91
2022 2,691 3,056 89.7 1.14
2023 3,226 3,454 76.4 1.07
2024 3,526 3,691 94 1.05
2025 4,072 4,277 83.5 1.05

Where the Cash Went

How to read this: why companies buy back shares, dividend yield explained.

Over the 10 fiscal years from 2016 to 2025 with dividend or share repurchase facts, estimated free cash flow totaled $26,905 million. That estimate uses the average of up to five years of capital expenditures, not each year's own, so it is not a reported figure.

In the 10 of those years with dividend payment facts, dividends paid totaled $25,312 million, 94.1% of the estimated free cash flow of those years. Estimated free cash flow was at least the dividends paid in 7 of those 10 years.

In 2025, dividends paid were $3,933 million, 94.0% of estimated free cash flow of $4,183 million.

Fiscal yearEstimated free cash flow (USD millions)Dividends paid (USD millions)Cash spent repurchasing shares (USD millions)Total returned (USD millions)Total as a percent of estimated free cash flow
2016 1,609 1,787 n/a 1,787 111.1%
2017 1,640 1,994 n/a 1,994 121.5%
2018 2,332 2,150 n/a 2,150 92.2%
2019 2,543 1,696 n/a 1,696 66.7%
2020 2,569 2,110 n/a 2,110 82.1%
2021 2,249 2,189 n/a 2,189 97.4%
2022 2,901 2,634 n/a 2,634 90.8%
2023 3,307 3,236 n/a 3,236 97.9%
2024 3,574 3,584 n/a 3,584 100.3%
2025 4,183 3,933 n/a 3,933 94.0%

Free cash flow here is an estimate: operating cash flow less the average of up to five years of capital expenditures. Cash spent repurchasing shares can include shares withheld to pay employees' taxes on stock awards. The entry n/a means the filings gave no usable figure, not that the amount was zero. Source: the company's annual reports to the SEC.

Revenue and Cash Margin

How to read this: earnings and margins.

Revenue was $1,756 million in 2007 and $6,521 million in 2025, a compound annual growth rate of 7.6% over 18 years.

Revenue rose 6.4% from 2024 to 2025.

Our estimated free cash flow was $4,183 million in 2025, 64.1% of revenue. In 2007 the estimated margin was 37.1%. This estimate charges each year with the average of up to five years of capital expenditures, so it is not the free cash flow the company reported.

Fiscal yearRevenue (USD millions)Estimated free cash flow (USD millions)Estimated free cash flow / revenue
2007 1,756 651 37.1%
2008 2,561 1,015 39.6%
2009 2,613 909 34.8%
2010 3,004 1,189 39.6%
2011 3,281 1,176 35.8%
2012 2,915 1,053 36.1%
2013 2,936 1,129 38.4%
2014 3,113 1,143 36.7%
2015 3,327 1,394 41.9%
2016 3,595 1,609 44.8%
2017 3,645 1,640 45.0%
2018 4,309 2,332 54.1%
2019 4,868 2,543 52.2%
2020 4,884 2,569 52.6%
2021 4,690 2,249 47.9%
2022 5,019 2,901 57.8%
2023 5,579 3,307 59.3%
2024 6,130 3,574 58.3%
2025 6,521 4,183 64.1%

Balance Sheet

How to read this: how debt and assets are compared, the current ratio.

In 2025, cash and equivalents were $4,417 million against total liabilities of $169,696 million, or 2.6% of total liabilities. Total liabilities include everything the company owes, not only borrowed money.

Total liabilities were 85.5% of total assets in 2025, compared with 61.2% in 2008, an increase of 24.3 percentage points.

Stockholders equity was $28,728 million in 2025, compared with $18,689 million in 2008, a rise of 53.7%.

Based on our estimated free cash flow, cash flow return on invested capital (CROIC) was 12.4% in 2025. Invested capital here is total assets less cash and current liabilities.

Fiscal yearTotal assets (USD millions)Cash and equivalents (USD millions)Total liabilities (USD millions)Stockholders equity (USD millions)
2008 48,159 298 29,470 18,689
2009 35,651 261 16,350 19,301
2010 35,046 855 14,986 20,060
2011 40,759 1,042 19,136 21,552
2012 38,863 1,605 17,358 21,425
2013 54,278 2,470 33,117 21,161
2014 72,242 1,366 51,318 20,924
2015 67,359 1,693 46,808 20,552
2016 69,369 1,869 49,029 20,341
2017 75,791 1,904 53,379 22,412
2018 77,476 1,375 51,510 25,965
2019 75,215 1,551 49,056 26,159
2020 124,660 1,633 98,308 26,352
2021 196,780 2,835 169,381 27,399
2022 174,176 2,720 147,297 26,879
2023 129,706 2,912 102,968 26,738
2024 137,447 2,892 110,960 26,487
2025 198,424 4,417 169,696 28,728

What the Price Implies

How to read this: discounted cash flow, intrinsic value.

At today's price of $307.56, our model's value equals that price if free cash flow grows an average of 19.3 percent a year over the 10 projection years. Our model assumes 4.0 percent a year for this stock, so the price implies growth of 19.3 percent, which is above the 4.0 percent our model assumes. This is the growth the price implies under our model, not a forecast of growth or a price target.

The table shows the same calculation at a price 20 percent lower and 20 percent higher than today's price, and the model's own growth rate at its fair price.

The model starts from the company's average free cash flow of $1,748 million, grows it over 10 years along the year-by-year growth path stored for this stock (the pace fades over the years, and the implied rate keeps that shape, so the rates here are 10-year averages), discounts it at 10.1 percent a year, adds a terminal value that grows 2.5 percent a year after year 10, adds the company's net worth, and divides by shares outstanding.

The baseline is the company's average free cash flow, and cyclical companies can mislead it.

CasePrice per shareAverage annual free cash flow growth
20 percent below the current price $246.05 15.0%
Current price $307.56 19.3%
20 percent above the current price $369.07 22.6%
Our model (stored fair price) $153.84 4.0%

Model assumptions: 10.1 percent discount rate, 2.5 percent terminal growth, 10 projection years. To try your own growth rate, use the intrinsic value calculator on this page. It uses a simpler single-rate model, so its results will not match the figures above exactly.

Price Versus Our Estimated Value

Every one of the 19 fiscal years we have for CME Group under its current filer shows positive free cash flow.

CME Group is priced at $307.56, above our fair value estimate of $153.84 and its safe value of $123.07.

Free cash flow from the first three years of data averaged $858 million, and from the last three $3,688 million: a sharp rise.

Year-to-year variability in free cash flow is fairly steady, measured at 17%.

The dividend yield for CME Group is 1.68%.

These figures are automated calculations from SEC filings and the recent price. They are not a recommendation to buy or sell. See how we estimate value.

Compared With Its Sector and Industry

How to read this: the price to earnings ratio.

Its trailing P/E ratio is 90% above the average for stocks in the Financial Services sector.

Its trailing P/E ratio is 48% below the average for stocks in the Capital Markets industry.

A P/E ratio depends on trailing earnings, which one-time items can distort, so a lower P/E is not by itself evidence of value.

Closest Industry Peers

These are companies in the Capital Markets industry, the ones closest in market capitalization to CME Group, limited to companies whose pages we publish. The figures come from our latest data for each company.

CompanyMarket cap (USD millions)P/EDividend yieldCash yieldPrice versus our estimate
CME Group (CME) 110,086 25.2 1.7% 1.6% 100% above
Interactive Brokers Group (IBKR) 121,296 27.2 0.4% - 501% above
Intercontinental Exchange (ICE) 95,006 23.2 1.2% 1.5% 91% above
The Charles Schwab Corporation (SCHW) 155,617 15.4 1.3% 0.6% 154% above
Nasdaq (NDAQ) 57,117 28.1 1.1% 1.2% 143% above
Cboe Global Markets (CBOE) 37,320 25.5 0.8% - 626% above
Virtu Financial (VIRT) 11,956 8.1 1.7% - 209% above

Industry labels are approximate, and companies in one industry can run quite different businesses, so a peer may not be a close match.

Ratios on different fiscal calendars are not strictly comparable, and a trailing P/E can be distorted by one-time items.

SEC Filer History

Every fiscal year on this page is reported by one SEC filer, CIK 1156375.

Each figure on this page comes from that filer.

Risks to This Analysis

How to read this: understanding investment risk.

  • These figures are automated calculations from SEC filings and the recent price. They may contain errors, and they do not reflect lawsuits, management changes, or other events the filings do not show.

How This Page Is Made

Latest annual report used
Fiscal year 2025
Price and market data last refreshed
2026-11-20
Model assumptions last reviewed
2026-11-09

Company figures come from the annual reports (Form 10-K) that each company files with the SEC, read from the SEC EDGAR company facts data. The share price and other market data come from a market data provider.

Free cash flow here is operating cash flow minus capital spending. To keep one unusual year from swinging the result, each year is charged with the average of up to five years of capital spending, so the figure is an estimate and not the free cash flow a company reports.

The fair price is the present value of ten years of projected free cash flow plus a terminal value, discounted at 10.1 percent a year, the long-run return of US stocks, with 2.5 percent growth after year ten. The figures on this page are estimates, not advice.

This analysis covers US companies that file 10-K annual reports. Free cash flow describes banks, real estate investment trusts and funds poorly, so treat their figures with extra caution. In the cash returned and balance sheet tables, a value of zero is treated as a gap in the data, not as a real zero.

Read the filings yourself: CME annual reports (10-K) on SEC EDGAR. To try your own growth rate, use the intrinsic value calculator on this page. Our editorial standards explain how Trendshare handles its sources and corrections.

Advertisement supports free stock analysis content.

Questions to Answer Before You Invest in CME

Does CME Group have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.

Worked example: CME

This example shows how we apply the Trendshare checklist to CME: earnings power, cash generation, valuation, and margin of safety.

We check: business quality, free cash flow, P/E, and margin of safety.

  1. Step 1 — Snapshot

    • Price: 307.56
    • Market cap: $110B
    • EPS: 12.2
  2. Step 2 — Valuation checks

    • P/E: 25.21
    • FCF yield: 1.6%
    • Date checked: Nov 20, 2026
  3. Step 3 — Margin of safety

    • Compare price to fair value and safety price.
    • Look for durable cash generation and reasonable leverage.
    • Decide if it passes your personal checklist.